Highlights Cerus Corporation

Equities

CERS

US1570851014

Market Closed - Nasdaq Other stock markets 21:00:00 09/05/2024 BST			5-day change	1st Jan Change
1.91 ^USD	+1.60%		+8.52%	-11.57%

05-02	Transcript : Cerus Corporation, Q1 2024 Earnings Call, May 02, 2024
05-02	Earnings Flash (CERS) CERUS CORPORATION Posts Q1 Revenue $43.4M, vs. Street Est of $38.4M	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (CERS) CERUS CORPORATION Posts Q1 Revenue $43.4M, vs. Street Est of $38.4M	05-02	MT
Cerus Corporation Reiterates Earnings Guidance for the Year Ending December 31, 2024	05-02	CI
Cerus Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets - Doubling Previous Shelf Life	03-26	CI
Cerus Says Intercept Blood System Meets Non-Inferiority Goal in Phase 3 Study; Shares Rise	03-19	MT
Cerus Shares Rise on Positive Results for Intercept Blood Cells Trial	03-19	DJ
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients	03-19	CI
Cerus Reiterates Full Year 2024 Product Revenue Guidance of $172-$175 Million	03-05	MT
Earnings Flash (CERS) CERUS CORPORATION Reports Q4 Revenue $53.3M, vs. Street Est of $52M	03-05	MT
Cerus Corporation Reiterates Product Revenue Guidance for the Full Year 2024	03-05	CI
Cerus Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-05	CI
Cerus Corporation Provides Revenue Guidance for the Fiscal Year 2024	01-08	CI
Cerus Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
Earnings Flash (CERS) CERUS CORPORATION Reports Q3 Revenue $47.3M, vs. Street Est of $42.8M	11-02	MT
Cerus Corporation Provides Product Revenue Guidance for the Full-Year 2023	11-02	CI
Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on Its Digital Marketplace	11-01	CI
Cerus Corporation Revises Revenue Guidance for the Year 2023	02/08/23	CI
Cerus Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	02/08/23	CI
Earnings Flash (CERS) CERUS CORPORATION Posts Q2 Revenue $47.7M, vs. Street Est of $41.8M	02/08/23	MT
Cerus Corporation Announces Follow-On Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate	05/06/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cerus Corporation

Equities

CERS

US1570851014

Highlights

Filters